Literature DB >> 31699575

Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy.

Takanori Ro1, Tetsuo Ota2, Tsukasa Saito3, Ou Oikawa2.   

Abstract

OBJECTIVE: This study examined how the effects of botulinum toxin therapy changed over time by sequential evaluation of clinical improvements in spasticity and contracture in 24 chronic-stage stroke patients on repeated botulinum toxin therapy who were receiving fewer rehabilitation interventions.
METHODS: Botulinum toxin injection was administered into the spastic muscle of the paralyzed upper or lower limb 5 times with at least 3-month intervals. Modified Ashworth Scale and range of motion were measured before and 2 weeks after each dose in the extremities to compare the first measurement value with subsequent values. Each predose value was also compared with the first predose value.
RESULTS: Compared with predose scores, Modified Ashworth Scale significantly improved in all flexors after 2 weeks from the first to fifth doses. Range of motion significantly improved in wrist dorsiflexion and ankle dorsiflexion. Comparison of values before each dose versus the first predose value showed significant improvement both in the Modified Ashworth Scale score of wrist flexors, finger flexors, and ankle planter flexors, and the range of motion of elbow extension, wrist dorsiflexion, and ankle dorsiflexion.
CONCLUSION: The comparison of predose values versus 2-week postdose values indicated that the effect of botulinum toxin formulation would not lessen after repeated injections with continuous improvements of Modified Ashworth Scale and range of motion. The comparison of predose values versus the first predose value also suggested that multiple injections of botulinum toxin formulation could be more effective in reducing spasticity and increasing the range of motion than a single injection.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Modified Ashworth Scale; Spasticity; botulinum toxin A therapy; range of motion; stroke

Mesh:

Substances:

Year:  2019        PMID: 31699575     DOI: 10.1016/j.jstrokecerebrovasdis.2019.104481

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  3 in total

1.  Clinical Significance and Value of Serum Homocysteine and Urine 11 Dehydrothromboxane B2 Combined with Transferrin-Specific Peptide in the Diagnosis of Cerebral Apoplexy.

Authors:  Junli Liu; Juan He; Chang Zhang
Journal:  Comput Math Methods Med       Date:  2022-05-17       Impact factor: 2.809

2.  Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke: the InTENSE randomised trial.

Authors:  Natasha A Lannin; Louise Ada; Coralie English; Julie Ratcliffe; Steven Faux; Mithu Palit; Senen Gonzalez; John Olver; Emma Schneider; Maria Crotty; Ian D Cameron
Journal:  BMC Neurol       Date:  2022-04-25       Impact factor: 2.903

3.  Predictors of Clinically Important Improvements in Motor Function and Daily Use of Affected Arm after a Botulinum Toxin A Injection in Patients with Chronic Stroke.

Authors:  Jen-Wen Hung; Wen-Chi Wu; Yi-Ju Chen; Ya-Ping Pong; Ku-Chou Chang
Journal:  Toxins (Basel)       Date:  2021-12-23       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.